Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

BACKGROUND: Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). METHODS: Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuncannon, Moire, Wong, Matthew, Jayamanne, Dasantha, Guo, Linxin, Cove, Nicola, Wheeler, Helen, Back, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518639/
https://www.ncbi.nlm.nih.gov/pubmed/31088401
http://dx.doi.org/10.1186/s12885-019-5678-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518639/
https://www.ncbi.nlm.nih.gov/pubmed/31088401
http://dx.doi.org/10.1186/s12885-019-5678-1

Ejemplares similares